PerkinElmer this week announced the appointment of Alan Fletcher as vice president of business development for the company’s Life and Analytical Sciences business.
Fletcher will be responsible for growing the Bio-discovery business through strategic partnerships and alliances and the introduction of new technologies for GPCR, kinase, and biomarker drug target classes, the company said in a statement.
Fletcher joins PerkinElmer from GE Healthcare, where he held multiple positions in its life science and discovery systems business units.
John Dineen has succeeded Joseph Hogan as president and CEO of GE Healthcare, the company announced this week.
Dineen is a 22-year veteran of GE and served as president and CEO of GE Transportation since 2005. Prior to that, he was vice president and general manager of Plastics at GE Advanced Materials.
Hogan took over as CEO of ABB, a power and automation technologies firm.
William Sullivan has joined HistoRx as senior vice president of diagnostics operations, the company said this week. The position is a newly created one.
Sullivan will be responsible for growing the diagnostics development process, overseeing the manufacture of the company’s diagnostic products, and growing diagnostic-related revenues.
Sullivan was previously vice president of corporate operations of Vermillion. Prior to that, he served as vice president of diagnostic manufacturing at Visible Genetics, and vice president of operations at the Nichols Institute Diagnostics, a subsidiary of Quest Diagnostics.
ProMetic Life Sciences said last week that Bruce Pritchard has replaced Stephane Archambault as the company’s CFO.
During the past two years, Pritchard has been CFO of ProMetic BioSciences, ProMetic’s UK division. In October 2007, he also became its vice president of corporate development.
The company also announced the resignation of Ronald Guttmann from its board, effective immediately, citing personal business activities.